CaMKll is a tightly regulated cardiac enzyme implicated in the development of heart failure, arrhythmias and cardiomyocyte survival. This proposal uses a unique set of genetically modified transgenic and knockout mice in which CaMKII5, the predominant CaMKII isoform in the heart, and its splice variants CaMKII6B and 5c are deleted or overexpressed so as to allow independent evaluation of their functions and effects at the nucleus, SR, and mitochondria. The proposal tests the hypothesis that the localization and molecular interactions of CaMKII create platforms which specify whether CaMKII activation effects changes in Ca handling, gene expression or mitochondrial cell death pathways. The proposed experiments study both in vivo function and in vitro cellular mechanisms.
In Aim #1 we ask whether there Is specificity in the activation of CaMKII In different subcellular compartments depending on the intervention.
Sub aims determine if exclusively expressed CaMKII6B and 6c are differentially activated, in which subcellular compartments CaMKII is activated, whether CaMKII is translocated following its activation, and whether the minor cardiac isoforms, CaMKlip and CaMKlly , alter CaMKIIS activation.
In Aim #2 we explore the consequences of subtype or compartmentalized CaMKII activity on cardiac function.
Sub aims determine whether nuclear CaMKII mediates hypertrophy in response to ET-1, whether SR localized CaMKII and its effects on RyR2 phosphorylation mediate heart failure (HF) development, and whether CaMKIISs and 5c subserve distinct and opposing functions in ischemia induced injury and HF.
Aim #3 investigates the proteins that interact with, are phosphorylated by and are transcriptionally activated in response to cardiac CaMKIISsand 6c activation using proteomics and gene arrays to explore distinct partners, phosphorylation targets and transcriptional programs.
The final Aim #4 addresses how CaMKII regulates mitochondrial cell survival.
Sub aims consider whether CaMKIISe and 5c differentially affect mitochondrial cell death pathways, if this occurs through proteins that are phosphorylated or transcriptionally regulated by CaMKII, and whether CaMKII directly associates with mitochondria to regulate mitochondrial function. The significance of this work comes from the increasing and compelling evidence that CaMKII is a novel potential therapeutic target for treatment of HF. Distinguishing the maladaptive and adaptive roles of CaMKII subtype activation at different cellular compartments and defining its targets is a means of understanding how to confer drug specificity.

Public Health Relevance

Cardiac disease and development of heart failure are amongst the primary causes of death in the nation and worldwide. We have discovered that a particular molecule called CaM kinase II is regulated in response to cardiac stress and injury and is a major factor in heart failure development. Here we seek to further understand what makes this enzyme active, where in the cell it works, and which of its effects would be useful therapeutic targets.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL080101-08
Application #
8496856
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
8
Fiscal Year
2013
Total Cost
$403,173
Indirect Cost
$141,373
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Hegyi, Bence; Bossuyt, Julie; Griffiths, Leigh G et al. (2018) Complex electrophysiological remodeling in postinfarction ischemic heart failure. Proc Natl Acad Sci U S A 115:E3036-E3044
Willeford, Andrew; Suetomi, Takeshi; Nickle, Audrey et al. (2018) CaMKII?-mediated inflammatory gene expression and inflammasome activation in cardiomyocytes initiate inflammation and induce fibrosis. JCI Insight 3:
Wood, Brent M; Simon, Mitchell; Galice, Samuel et al. (2018) Cardiac CaMKII activation promotes rapid translocation to its extra-dyadic targets. J Mol Cell Cardiol 125:18-28
Hegyi, Bence; Bossuyt, Julie; Ginsburg, Kenneth S et al. (2018) Altered Repolarization Reserve in Failing Rabbit Ventricular Myocytes: Calcium and ?-Adrenergic Effects on Delayed- and Inward-Rectifier Potassium Currents. Circ Arrhythm Electrophysiol 11:e005852
Yan, Jiajie; Zhao, Weiwei; Thomson, Justin K et al. (2018) Stress Signaling JNK2 Crosstalk With CaMKII Underlies Enhanced Atrial Arrhythmogenesis. Circ Res 122:821-835
Surdo, Nicoletta C; Berrera, Marco; Koschinski, Andreas et al. (2017) FRET biosensor uncovers cAMP nano-domains at ?-adrenergic targets that dictate precise tuning of cardiac contractility. Nat Commun 8:15031
Ma, Xiaolong; Chen, Chao; Veevers, Jennifer et al. (2017) CRISPR/Cas9-mediated gene manipulation to create single-amino-acid-substituted and floxed mice with a cloning-free method. Sci Rep 7:42244
Lang, Di; Sato, Daisuke; Jiang, Yanyan et al. (2017) Calcium-Dependent Arrhythmogenic Foci Created by Weakly Coupled Myocytes in the Failing Heart. Circ Res 121:1379-1391
Bers, Donald M (2017) CALMing Down Arrhythmogenic Calmodulinopathies via a Precision Medicine Approach. Circ Res 120:3-4
Pereira, Laƫtitia; Bare, Dan J; Galice, Samuel et al. (2017) ?-Adrenergic induced SR Ca2+ leak is mediated by an Epac-NOS pathway. J Mol Cell Cardiol 108:8-16

Showing the most recent 10 out of 233 publications